Bio2Business Featured Speaker Series

SHAREemail the linkcopy link to Clipboard
Bridging Capability Gaps in Drug Discovery in Fibrotic Diseases
20 June: 11:30 - 12:30
Dr Simon Cruwys, Co-founder and Director, TherapeutAix
ABSTRACT
In March 2019, the Medicines Discovery Catapult hosted a workshop led by the team from TherapeutAix , with participation from key stakeholders, including representatives from CROs and Pharma. The focus was on bridging capability gaps in drug discovery in fibrotic disease. This session will describe the workshop objectives, process and output from different participant perspectives and highlight future opportunities for collaboration in capability development and validation.

BIOGRAPHY
Simon Cruwys is Director of Pharmacology, TherapeutAix UG. Prior to the founding of TherapeutAix in 2018, Simon was Head of the Innovative Medicines Unit, Grünenthal Innovation. In this role, Simon led a team responsible for in-licensing molecules and delivering them to Clinical proof of concept. He has over 30 years experience in academic and industry research. As a project leader, he has a track record of delivery from Lead Identification  through to clinical validation. Prior to Grünenthal, Simon worked for AstraZeneca where he was lead for both small molecule and antibody projects.

 

Graeme Wilkinson is Head of Virtual R&D at the Medicines Discovery Catapult and leads a team responsible for helping UK drug discovery innovators develop and deliver their projects to Clinical proof of concept. He has 30 years’ experience in drug discovery and early development research in both academia and industry with a track record of delivery from Lead Identification through to clinical validation. Prior to MDC, Graeme has worked in start up and spin out as well as large pharma and across a number of therapy areas.

 

 

COMPANY PROFILE
TherapeutAix

 

Founded in 2018, TherapeutAix is a life sciences consultancy company based in Aachen (Aix-la-Chapelle), Germany. The 4 founders have successfully worked together for over 4 years, conducting project reviews, developing strategies and operationalization via a R&D Network – establishing best practices that now form the core of TherapeutAix. We have a passion for doing the right thing with the right molecules. Our mission is to help investors and project teams focus on the next step, and progress the right assets through the right decision-making programs with a line of sight to the next value inflection point and, ultimately, the clinic. The team at TherapeutAix works as an extension of the client team, providing a science-led collaboration to identify challenges, plan solutions and obtain supporting data.

 

Medicines Discovery Catapult

 

Medicines Discovery Catapult is a national facility connecting the UK community to accelerate innovative drug discovery.We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs to drive the development and industrialisation of new approaches for the discovery of new medicines.

By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.Ultimately, new industrialised technologies are vital for delivering new medicines to patients, faster.

 

Learn more about BOS2019
BOS Testimonials|2017                      BOS Testimonials|2018